Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial

Study limitation reported by the research below: “The study was conducted exclusively in Japan (≥75 years), which may limit applicability to other ethnic groups or health systems with different treatment thresholds for older adults.”